AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

Research

MEDIA AVAILABILITY: Durable End to AIDS Will Require HIV Vaccine Development

NIAID

Recent Scientific Advances Offer Promising Areas for Further Exploration   WHAT: Broader global access to lifesaving antiretroviral therapies and wider implementation of proven HIV prevention strategies could potentially control and perhaps end the HIV/AIDS pandemic. However, a safe and at least moderately effective HIV vaccine is needed to reach this goal more expeditiously and in…

Scientists Discover Hepatitis C Virus Can Remain Infectious Outside of the Body for Up to 6 Weeks

Ronald Valdiserri

A recent study by researchers from the Yale Schools of Medicine and Public Health revealed that the hepatitis C virus (HCV) can remain infectious for up to 6 weeks on surfaces at room temperature—resulting in a much longer period for potential transmission than was previously appreciated.  Prior to this study, scientists believed that HCV could…

20 Years of Discovery: The Women’s Interagency HIV Study

facuci_160x160

Twenty years ago, when most HIV/AIDS patients were men, the National Institutes of Health (NIH) launched the Women’s Interagency HIV Study (WIHS), observing women in the United States who are either HIV-infected or at risk for becoming infected. Since then, results from the WIHS have informed unique aspects of care and treatment for HIV-infected women…

NIH Names Leadership, Research Units for Restructured HIV/AIDS Clinical Trials Networks

nih logo

The National Institute of Allergy and Infectious Diseases (NIAID) has selected the principal investigators and clinical trials units (CTUs) that will lead and conduct the research of the five restructured HIV/AIDS clinical trials networks through 2021. The new structure is designed to create a broader, more flexible and more collaborative approach to the networks’ research priorities, which…

FDA approves Sovaldi for chronic hepatitis C

FDA

Drug is third with breakthrough therapy designation to receive FDA approval The U.S. Food and Drug Administration today approved Sovaldi (sofosbuvir) to treat chronic hepatitis C virus (HCV) infection. Sovaldi is the first drug that has demonstrated safety and efficacy to treat certain types of HCV infection without the need for co-administration of interferon. “Today’s…

NIH announces plan to increase funding toward a cure for HIV/AIDS

NIH logo

At a White House event today to mark the 25th annual World AIDS Day, President Obama announced that the National Institutes of Health plans to redirect AIDS research funds to expand support for research directed toward a cure for HIV. NIH plans to invest an additional $100 million over the next three fiscal years on this increasingly promising area…

Striving for the AIDS End Game: Translating Research Promise Into Public Health Success

Anthony Fauci

Dec. 1, 2013 marks the 25th annual commemoration of World AIDS Day. In highlighting this day, partners in the fight against HIV/AIDS will champion bold goals, such as “ending AIDS” and “getting to zero.” With the sober recognition that 35.3 million people are living with HIV/AIDS today, these goals may seem unattainable, perhaps even fanciful…

NIH Statement on World AIDS Day 2013

NIH logo

In the 25 years that have passed since the first annual commemoration of World AIDS Day, extraordinary scientific progress has been made in the fight against HIV/AIDS. That progress has turned an HIV diagnosis from an almost-certain death sentence to what is now for many, a manageable medical condition and nearly normal lifespan. We have…